U.S. flag

An official website of the United States government

NCBI Bookshelf. A service of the National Library of Medicine, National Institutes of Health.

Gold LS, Lee CI, Devine B, et al. Imaging Techniques for Treatment Evaluation for Metastatic Breast Cancer [Internet]. Rockville (MD): Agency for Healthcare Research and Quality (US); 2014 Oct. (Technical Briefs, No. 17.)

Cover of Imaging Techniques for Treatment Evaluation for Metastatic Breast Cancer

Imaging Techniques for Treatment Evaluation for Metastatic Breast Cancer [Internet].

Show details

References

1.
American Cancer Society. Cancer Facts & Figures 2013. Atlanta, GA: 2013. [November 6, 2013]. www​.cancer.org/acs/groups​/content/@epidemiologysurveilance​/documents​/document/acspc-036845.pdf.
2.
National Comprehensive Cancer Network Inc. Breast Cancer. NCCN; 2013. [November 6, 2013]. 3/11/2013. www​.nccn.org/professionals​/physician_gls/pdf/breast.pdf.
3.
National Institute for Health and Clinical Excellence (NICE). Advanced Breast Cancer: Diagnosis and Treatment National Collaborating Centre for Cancer National Institute for Health and Clinical Excellence. London: 2009. [November 6, 2013]. www​.nice.org.uk/nicemedia​/live/11778/43305/43305.pdf.
4.
Centers for Medicare and Medicaid Services (CMS). Physician Fee Schedule. 2009. [November 6, 2013]. http://chfs​.ky.gov/nr​/rdonlyres/4fd6f67c-6c97-4061-a9fd-2441467201f2​/0/mdfee2009rev4909r2.pdf.
5.
Centers for Medicare and Medicaid Services (CMS). Medicare Program: Changes to the Hospital Outpatient Prospective Payment System and CY 2009 Payment Rates CMS. 2009. www​.cms.gov/Medicare​/Medicare-Fee-for-Service-Payment​/HospitalOutpatientPPS​/downloads/CMS-1404-FC​.pdf. [PubMed: 20166279]
6.
Cardoso F, Costa A, Norton L, et al. 1st International consensus guidelines for advanced breast cancer (ABC 1). Breast. 2012 Jun;21(3):242–52. [PubMed: 22425534]
7.
Lin NU, Thomssen C, Cardoso F, et al. International guidelines for management of metastatic breast cancer (MBC) from the European School of Oncology (ESO)-MBC Task Force: Surveillance, staging, and evaluation of patients with early-stage and metastatic breast cancer. Breast. 2013 Jun;22(3):203–10. [PubMed: 23601761]
8.
Costelloe CM, Rohren EM, Madewell JE, et al. Imaging bone metastases in breast cancer: techniques and recommendations for diagnosis. Lancet Oncol. 2009 Jun;10(6):606–14. [PubMed: 19482249]
9.
Buijs M, Kamel IR, Vossen JA, et al. Assessment of metastatic breast cancer response to chemoembolization with contrast agent enhanced and diffusion-weighted MR imaging. J Vasc Interv Radiol. 2007 Aug;18(8):957–63. [PubMed: 17675611]
10.
Cachin F, Prince HM, Hogg A, et al. Powerful prognostic stratification by [18F]fluorodeoxyglucose positron emission tomography in patients with metastatic breast cancer treated with high-dose chemotherapy. J Clin Oncol. 2006 Jul 1;24(19):3026–31. [PubMed: 16717291]
11.
Cheng J, Lei L, Xu J, et al. 18F-fluoromisonidazole PET/CT: a potential tool for predicting primary endocrine therapy resistance in breast cancer. J Nucl Med. 2013 Mar;54(3):333–40. [PubMed: 23401605]
12.
Contractor K, Aboagye EO, Jacob J, et al. Monitoring early response to taxane therapy in advanced breast cancer with circulating tumor cells and [(18)F] 3 -deoxy-3 -fluorothymidine PET: a pilot study. Biomark Med. 2012 Apr;6(2):231–3. [PubMed: 22448798]
13.
Contractor KB, Kenny LM, Stebbing J, et al. [18F]-3′Deoxy-3′-fluorothymidine positron emission tomography and breast cancer response to docetaxel. Clin Cancer Res. 2011 Dec 15;17(24):7664–72. [PubMed: 22028493]
14.
De Giorgi U, Valero V, Rohren E, et al. Circulating tumor cells and [18F]fluorodeoxyglucose positron emission tomography/computed tomography for outcome prediction in metastatic breast cancer. J Clin Oncol. 2009 Jul 10;27(20):3303–11. [PubMed: 19451443]
15.
Dose Schwarz J, Bader M, Jenicke L, et al. Early prediction of response to chemotherapy in metastatic breast cancer using sequential 18F-FDG PET. J Nucl Med. 2005 Jul;46(7):1144–50. [PubMed: 16000283]
16.
Haug AR, Tiega Donfack BP, Trumm C, et al. 18F-FDG PET/CT predicts survival after radioembolization of hepatic metastases from breast cancer. J Nucl Med. 2012 Mar;53(3):371–7. [PubMed: 22331219]
17.
Huyge V, Garcia C, Alexiou J, et al. Heterogeneity of metabolic response to systemic therapy in metastatic breast cancer patients. Clin Oncol (R Coll Radiol). 2010 Dec;22(10):818–27. [PubMed: 20554438]
18.
Kenny L, Coombes RC, Vigushin DM, et al. Imaging early changes in proliferation at 1 week post chemotherapy: a pilot study in breast cancer patients with 3′-deoxy-3′-[18F]fluorothymidine positron emission tomography. Eur J Nucl Med Mol Imaging. 2007 Sep;34(9):1339–47. [PubMed: 17333178]
19.
Linden HM, Kurland BF, Peterson LM, et al. Fluoroestradiol positron emission tomography reveals differences in pharmacodynamics of aromatase inhibitors, tamoxifen, and fulvestrant in patients with metastatic breast cancer. Clin Cancer Res. 2011 Jul 15;17(14):4799–805. [PMC free article: PMC3139698] [PubMed: 21750198]
20.
Linden HM, Stekhova SA, Link JM, et al. Quantitative fluoroestradiol positron emission tomography imaging predicts response to endocrine treatment in breast cancer. J Clin Oncol. 2006 Jun 20;24(18):2793–9. [PubMed: 16682724]
21.
Mortazavi-Jehanno N, Giraudet AL, Champion L, et al. Assessment of response to endocrine therapy using FDG PET/CT in metastatic breast cancer: a pilot study. Eur J Nucl Med Mol Imaging. 2012 Mar;39(3):450–60. [PubMed: 22183107]
22.
Pio BS, Park CK, Pietras R, et al. Usefulness of 3′-[F-18]fluoro-3′-deoxythymidine with positron emission tomography in predicting breast cancer response to therapy. Mol Imaging Biol. 2006 Jan-Feb;8(1):36–42. [PubMed: 16362149]
23.
Specht JM, Tam SL, Kurland BF, et al. Serial 2-[18F] fluoro-2-deoxy-D-glucose positron emission tomography (FDG-PET) to monitor treatment of bone-dominant metastatic breast cancer predicts time to progression (TTP). Breast Cancer Res Treat. 2007 Sep;105(1):87–94. [PubMed: 17268819]
24.
Tateishi U, Gamez C, Dawood S, et al. Bone metastases in patients with metastatic breast cancer: morphologic and metabolic monitoring of response to systemic therapy with integrated PET/CT. Radiology. 2008 Apr;247(1):189–96. [PubMed: 18372468]
25.
Hayashi N, Costelloe CM, Hamaoka T, et al. A prospective study of bone tumor response assessment in metastatic breast cancer. Clin Breast Cancer. 2013 Feb;13(1):24–30. [PMC free article: PMC3863546] [PubMed: 23098575]
26.
American College of Radiology Imaging Network. About Imaging Agents Or Tracers. 2013. [November 6, 2013]. www​.acrin.org/PATIENTS​/ABOUTIMAGINGEXAMSANDAGENTS​/ABOUTIMAGINGAGENTSORTRACERS​.aspx.
27.
Gold LS, Klein G, Carr L, et al. The emergence of diagnostic imaging technologies in breast cancer: discovery, regulatory approval, reimbursement, and adoption in clinical guidelines. Cancer Imaging. 2012;12(1):13–24. [PMC free article: PMC3266577] [PubMed: 22275726]
28.
Berger A. Magnetic resonance imaging. BMJ. 2002 Jan 5;324(7328):35. [PMC free article: PMC1121941] [PubMed: 11777806]
29.
Li A, Wong CS, Wong MK, et al. Acute adverse reactions to magnetic resonance contrast media--gadolinium chelates. Br J Radiol. 2006 May;79(941):368–71. [PubMed: 16632615]
30.
Robbins JB, Pozniak MA. Contrast Media Tutorial. Madison, WI: University of Wisconsin, Department of Radiology; 2010. [November 6 2013]. www​.radiology.wisc.edu​/fileShelf/contrastCorner​/files/ContrastAgentsTutorial.pdf.
31.
Podoloff D, Advani R, Allred C, et al. NCCN task force report: positron emission tomography (PET)/computed tomography (CT) scanning in cancer. J Natl Compr Canc Netw. 2007 May;5 Suppl 1:S1–S22. quiz S3-2. [PubMed: 17509259]
32.
U.S. Food and Drug Administration. What are the Radiation Risks from CT? U.S. FDA; 2009. [February 20 2014]. www​.fda.gov/radiation-emittingproducts​/radiationemittingproductsandprocedures​/medicalimaging​/medicalx-rays/ucm115329.htm.
33.
Zaidi H, Del Guerra A. An outlook on future design of hybrid PET/MRI systems. Medical physics. 2011;38:5667. [PubMed: 21992383]
34.

Views

  • PubReader
  • Print View
  • Cite this Page
  • PDF version of this title (637K)

Related information

  • PMC
    PubMed Central citations
  • PubMed
    Links to PubMed

Recent Activity

Your browsing activity is empty.

Activity recording is turned off.

Turn recording back on

See more...